205 related articles for article (PubMed ID: 38326311)
1. ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97.
Pozner A; Li L; Verma SP; Wang S; Barrott JJ; Nelson ML; Yu JSE; Negri GL; Colborne S; Hughes CS; Zhu JF; Lambert SL; Carroll LS; Smith-Fry K; Stewart MG; Kannan S; Jensen B; John CM; Sikdar S; Liu H; Dang NH; Bourdage J; Li J; Vahrenkamp JM; Mortenson KL; Groundland JS; Wustrack R; Senger DL; Zemp FJ; Mahoney DJ; Gertz J; Zhang X; Lazar AJ; Hirst M; Morin GB; Nielsen TO; Shen PS; Jones KB
Nat Commun; 2024 Feb; 15(1):1165. PubMed ID: 38326311
[TBL] [Abstract][Full Text] [Related]
2. ASPSCR1-TFE3 reprograms transcription by organizing enhancer loops around hexameric VCP/p97.
Pozner A; Verma SP; Li L; Wang S; Barrott JJ; Nelson ML; Yu JSE; Negri GL; Colborne S; Hughes CS; Zhu JF; Lambert SL; Carroll LS; Smith-Fry K; Stewart MG; Kannan S; Jensen B; Mortenson KL; John C; Sikdar S; Liu H; Dang NH; Bourdage J; Li J; Vahrenkamp JM; Groundland JS; Wustrack R; Senger DL; Zemp FJ; Mahoney DJ; Gertz J; Zhang X; Lazar AJ; Hirst M; Morin GB; Nielsen TO; Shen PS; Jones KB
bioRxiv; 2023 Oct; ():. PubMed ID: 37873234
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
[TBL] [Abstract][Full Text] [Related]
4. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein.
Kobos R; Nagai M; Tsuda M; Merl MY; Saito T; Laé M; Mo Q; Olshen A; Lianoglou S; Leslie C; Ostrovnaya I; Antczak C; Djaballah H; Ladanyi M
J Pathol; 2013 Apr; 229(5):743-754. PubMed ID: 23288701
[TBL] [Abstract][Full Text] [Related]
5. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age, and stage.
Ellis CL; Eble JN; Subhawong AP; Martignoni G; Zhong M; Ladanyi M; Epstein JI; Netto GJ; Argani P
Mod Pathol; 2014 Jun; 27(6):875-86. PubMed ID: 24309327
[TBL] [Abstract][Full Text] [Related]
6. Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases.
Hodge JC; Pearce KE; Wang X; Wiktor AE; Oliveira AM; Greipp PT
Mod Pathol; 2014 Jan; 27(1):113-27. PubMed ID: 23828314
[TBL] [Abstract][Full Text] [Related]
7. ASPSCR1-TFE3 fusion in a case of Xp11 translocation PEComa of the liver: are ASPSCR1-TFE3 fusion-bearing tumours Xp11 translocation PEComa or alveolar soft part sarcoma?
Chai J; Ma J; Liu Y; Zhao D; Yin Z; Wang Z; Fan L
Pathology; 2023 Apr; 55(3):416-419. PubMed ID: 36104270
[No Abstract] [Full Text] [Related]
8. TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers.
Argani P; Zhong M; Reuter VE; Fallon JT; Epstein JI; Netto GJ; Antonescu CR
Am J Surg Pathol; 2016 Jun; 40(6):723-37. PubMed ID: 26975036
[TBL] [Abstract][Full Text] [Related]
9. A novel VCP::TFE3 gene fusion resulting from t(X;9)(p11.23;p13.3) chromosome translocation in TFE3 rearranged renal cancer cell carcinoma.
Kuentz MA; Blons H; Gimenez-Roqueplo AP; Just PA; Laurent-Puig P; Mejean A; Oudard S; Verkarre V
Genes Chromosomes Cancer; 2023 Jun; 62(6):361-366. PubMed ID: 36695651
[TBL] [Abstract][Full Text] [Related]
10. PEComa-like Neoplasms Characterized by ASPSCR1-TFE3 Fusion: Another Face of TFE3-related Mesenchymal Neoplasia.
Argani P; Wobker SE; Gross JM; Matoso A; Fletcher CDM; Antonescu CR
Am J Surg Pathol; 2022 Aug; 46(8):1153-1159. PubMed ID: 35848761
[TBL] [Abstract][Full Text] [Related]
11. Technique for differentiating alveolar soft part sarcoma from other tumors in paraffin-embedded tissue: comparison of immunohistochemistry for TFE3 and CD147 and of reverse transcription polymerase chain reaction for ASPSCR1-TFE3 fusion transcript.
Tsuji K; Ishikawa Y; Imamura T
Hum Pathol; 2012 Mar; 43(3):356-63. PubMed ID: 21835426
[TBL] [Abstract][Full Text] [Related]
12. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
13. PEComa with ASPSCR1::TFE3 fusion: expanding the molecular genetic spectrum of TFE3-rearranged PEComa with an emphasis on overlap with alveolar soft part sarcoma.
Zhao M; Huang Y; Yin X; Xu J; Sun Y; Wang J
Histopathology; 2024 Feb; 84(3):482-491. PubMed ID: 37936565
[TBL] [Abstract][Full Text] [Related]
14. ASPSCR1::TFE3 orchestrates the angiogenic program of alveolar soft part sarcoma.
Tanaka M; Chuaychob S; Homme M; Yamazaki Y; Lyu R; Yamashita K; Ae K; Matsumoto S; Kumegawa K; Maruyama R; Qu W; Miyagi Y; Yokokawa R; Nakamura T
Nat Commun; 2023 Apr; 14(1):1957. PubMed ID: 37029109
[TBL] [Abstract][Full Text] [Related]
15. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas.
Aulmann S; Longerich T; Schirmacher P; Mechtersheimer G; Penzel R
Histopathology; 2007 Jun; 50(7):881-6. PubMed ID: 17543078
[TBL] [Abstract][Full Text] [Related]
16. Comparative genomics incorporating translocation renal cell carcinoma mouse model reveals molecular mechanisms of tumorigenesis.
Prakasam G; Mishra A; Christie A; Miyata J; Carrillo D; Tcheuyap VT; Ye H; Do QN; Wang Y; Reig Torras O; Butti R; Zhong H; Gagan J; Jones KB; Carroll TJ; Modrusan Z; Durinck S; Requena-Komuro MC; Williams NS; Pedrosa I; Wang T; Rakheja D; Kapur P; Brugarolas J
J Clin Invest; 2024 Feb; 134(7):. PubMed ID: 38386415
[TBL] [Abstract][Full Text] [Related]
17. TFE3 Xp11.2 Translocation Renal Cell Carcinoma Mouse Model Reveals Novel Therapeutic Targets and Identifies GPNMB as a Diagnostic Marker for Human Disease.
Baba M; Furuya M; Motoshima T; Lang M; Funasaki S; Ma W; Sun HW; Hasumi H; Huang Y; Kato I; Kadomatsu T; Satou Y; Morris N; Karim BO; Ileva L; Kalen JD; Wilan Krisna LA; Hasumi Y; Sugiyama A; Kurahashi R; Nishimoto K; Oyama M; Nagashima Y; Kuroda N; Araki K; Eto M; Yao M; Kamba T; Suda T; Oike Y; Schmidt LS; Linehan WM
Mol Cancer Res; 2019 Aug; 17(8):1613-1626. PubMed ID: 31043488
[TBL] [Abstract][Full Text] [Related]
18. TMED6-COG8 is a novel molecular marker of TFE3 translocation renal cell carcinoma.
Xu Y; Rao Q; Xia Q; Shi S; Shi Q; Ma H; Lu Z; Chen H; Zhou X
Int J Clin Exp Pathol; 2015; 8(3):2690-9. PubMed ID: 26045774
[TBL] [Abstract][Full Text] [Related]
19. RNA sequencing of Xp11 translocation-associated cancers reveals novel gene fusions and distinctive clinicopathologic correlations.
Wang XT; Xia QY; Ye SB; Wang X; Li R; Fang R; Shi SS; Zhang RS; Tan X; Chen JY; Sun K; Teng XD; Ma HH; Lu ZF; Zhou XJ; Rao Q
Mod Pathol; 2018 Sep; 31(9):1346-1360. PubMed ID: 29713041
[TBL] [Abstract][Full Text] [Related]
20. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation-associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum.
Rao Q; Williamson SR; Zhang S; Eble JN; Grignon DJ; Wang M; Zhou XJ; Huang W; Tan PH; Maclennan GT; Cheng L
Am J Surg Pathol; 2013 Jun; 37(6):804-15. PubMed ID: 23598965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
